{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Said R"],"funding":["NCI NIH HHS"],"pagination":["705-14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3742831"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(5)"],"pubmed_abstract":["<h4>Background</h4>Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer.<h4>Methods</h4>We retrospectively reviewed and analyzed the clinical features and response to standard systemic therapy of 145 patients with documented tumor p53 mutational status (mutant-type [mtp53] vs. wild-type [wtp53]) referred to the Clinical Center for Targeted Therapy.<h4>Results</h4>Sixty-six (45.5%) patients had mtp53. Mutations in p53 occurred more frequently in older patients (p= 0.015) and in Caucasians (p=0.024). The incidence of liver metastases was 69.2% vs. 43%, p=0.002 in mtp53 and wtp53, respectively. PTEN loss by immunohistochemistry was f"],"journal":["Oncotarget"],"pubmed_title":["P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy."],"pmcid":["PMC3742831"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Said R","Warneke CL","Fu S","Janku F","Kurzrock R","Piha-Paul S","Hong DS","Naing A","Falchook GS","Lee JJ","Tsimberidou AM","Wheler JJ"],"additional_accession":[]},"is_claimable":false,"name":"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.","description":"<h4>Background</h4>Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer.<h4>Methods</h4>We retrospectively reviewed and analyzed the clinical features and response to standard systemic therapy of 145 patients with documented tumor p53 mutational status (mutant-type [mtp53] vs. wild-type [wtp53]) referred to the Clinical Center for Targeted Therapy.<h4>Results</h4>Sixty-six (45.5%) patients had mtp53. Mutations in p53 occurred more frequently in older patients (p= 0.015) and in Caucasians (p=0.024). The incidence of liver metastases was 69.2% vs. 43%, p=0.002 in mtp53 and wtp53, respectively. PTEN loss by immunohistochemistry was f","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 May","modification":"2025-04-19T03:46:48.865Z","creation":"2019-03-27T01:14:32Z"},"accession":"S-EPMC3742831","cross_references":{"pubmed":["23670029"],"doi":["10.18632/oncotarget.974"]}}